S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$30.94
+1.36 (+4.60 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.72
Now: $30.94
$31.26
50-Day Range
$26.42
MA: $29.42
$31.45
52-Week Range
$13.12
Now: $30.94
$31.99
Volume566,204 shs
Average Volume518,934 shs
Market Capitalization$1.63 billion
P/E Ratio12.84
Dividend YieldN/A
Beta1.38
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Employees464
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.74 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Market Cap$1.63 billion
Next Earnings Date2/25/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.42 out of 5 stars

Medical Sector

523rd out of 1,958 stocks

Pharmaceutical Preparations Industry

259th out of 772 stocks

Analyst Opinion: 1.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$30.94
+1.36 (+4.60 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Supernus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SUPN, but not buy additional shares or sell existing shares.
View analyst ratings for Supernus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Supernus Pharmaceuticals?

Wall Street analysts have given Supernus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Tuesday, November, 3rd. The specialty pharmaceutical company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.47. The specialty pharmaceutical company earned $155.10 million during the quarter, compared to the consensus estimate of $130.76 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 20.02% and a net margin of 27.09%. The business's revenue was up 52.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.54 earnings per share.
View Supernus Pharmaceuticals' earnings history
.

How has Supernus Pharmaceuticals' stock price been impacted by COVID-19?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 91.6% and is now trading at $30.94.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SUPN?

3 brokerages have issued 1-year price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $27.67 in the next year. This suggests that the stock has a possible downside of 10.6%.
View analysts' price targets for Supernus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 60, Pay $1.49M)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 64, Pay $537.2k)
  • Ms. Tami T. Martin, Sr. VP of Regulatory Affairs (Age 66, Pay $450.28k)
  • Dr. Stefan K. F. Schwabe, Consultant (Age 69, Pay $584.04k)
  • Mr. James Patrick Kelly, Exec. VP & CFO (Age 55)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
  • Mr. Taylor Raiford, VP of Sales
  • Dr. Bryan A. Roecklein, VP of Corp. Devel.
  • Mr. Frank Mottola, Sr. VP of Quality, GMP Operations & Information Technology (Age 49)
  • Dr. Jonathan Rubin, Sr. VP & Chief Medical Officer (Age 60)

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.92%), Renaissance Technologies LLC (3.51%), GW&K Investment Management LLC (2.50%), Fuller & Thaler Asset Management Inc. (2.47%), Aequim Alternative Investments LP (2.47%) and Ashford Capital Management Inc. (2.32%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar and Stefan KF Schwabe.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Burney Co., Armistice Capital LLC, Matarin Capital Management LLC, Price T Rowe Associates Inc. MD, Victory Capital Management Inc., Aristotle Capital Boston LLC, Glenmede Trust Co. NA, and Northern Trust Corp. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, Gregory S Patrick, and Stefan KF Schwabe.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was acquired by a variety of institutional investors in the last quarter, including Aequim Alternative Investments LP, Stephens Investment Management Group LLC, HealthInvest Partners AB, SummerHaven Investment Management LLC, Ashford Capital Management Inc., Fuller & Thaler Asset Management Inc., GW&K Investment Management LLC, and Royce & Associates LP.
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $30.94.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.63 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 464 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

Where are Supernus Pharmaceuticals' headquarters?

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.